A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis

被引:95
作者
Mayell, S. J.
Munck, A. [2 ,4 ]
Craig, J. V.
Sermet, I. [3 ]
Brownlee, K. G. [5 ]
Schwarz, M. J. [6 ]
Castellani, C. [7 ]
Southern, K. W. [1 ]
机构
[1] Univ Liverpool, Royal Liverpool Childrens Hosp, Inst Child Hlth, Liverpool L12 2AP, Merseyside, England
[2] Hop Robert Debre, AP HP, F-75019 Paris, France
[3] Hop Necker Enfants Malad, Paris, France
[4] AFDPHE, Paris, France
[5] St James Univ Hosp, Reg CF Unit, Leeds LS9 7TF, W Yorkshire, England
[6] St Marys Hosp, Reg Mol Genet Serv, Manchester M13 0JH, Lancs, England
[7] Azienda Osped, Cyst Fibrosis Ctr, Verona, Italy
关键词
Cystic fibrosis; Neonatal screening; Management; Sweat test; Gene analysis; IMMUNOREACTIVE TRYPSINOGEN; MUTATION ANALYSIS;
D O I
10.1016/j.jcf.2008.09.005
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Screening newborns for cystic fibrosis (CF) is considered to be an ethical undertaking in regions with a significant incidence of the condition. Current screening protocols result in recognition of infants with an equivocal diagnosis. A survey of European practice suggested inconsistencies in the evaluation and management of these infants. We have undertaken a consensus process using a modified Delphi method. This has enabled input of CF specialists from a wide geographical area to a rigorous process that has provided a clear pathway to a consensus statement. A core group produced 21 statements, which were modified over a series of three rounds (including a meeting arranged at the European CF Conference). A final document of 19 statements was produced, all of which achieved a satisfactory level of consensus. The statements cover four themes; sweat testing, further assessments and investigations, review arrangements and database. This consensus document will provide guidance to CF specialists with established screening programmes and those who are in the process of implementing newborn screening in their region. Crown Copyright (C) 2008 Published by Elsevier B.V on behalf of European Cystic Fibrosis Society. All rights reserved.
引用
收藏
页码:71 / 78
页数:8
相关论文
共 16 条
  • [1] Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
    Castellani, C.
    Cuppens, H.
    Macek, M., Jr.
    Cassinian, J. J.
    Kerern, E.
    Durie, P.
    Tullis, E.
    Assael, B. M.
    Bombieri, C.
    Brown, A.
    Casals, T.
    Claustres, M.
    Cutting, G. R.
    Dequeker, E.
    Dodge, J.
    Doull, I.
    Farrell, P.
    Ferec, C.
    Girodon, E.
    Johannesson, M.
    Kerem, B.
    Knowles, M.
    Munck, A.
    Pignatti, P. F.
    Radojkovic, D.
    Rizzotti, P.
    Schwarz, M.
    Stuhnnann, M.
    Tzetis, M.
    Zielenski, J.
    Elborn, J. S.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (03) : 179 - 196
  • [2] Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers
    Castellani, C
    Picci, L
    Scarpa, M
    Dechecchi, MC
    Zanolla, L
    Assael, BM
    Zacchello, F
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2005, 135A (02) : 142 - 144
  • [3] CROSSLEY JR, 1979, LANCET, V1, P472
  • [4] Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes - The polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation
    Cuppens, H
    Lin, W
    Jaspers, M
    Costes, B
    Teng, H
    Vankeerberghen, A
    Jorissen, M
    Droogmans, G
    Reynaert, I
    Goossens, M
    Nilius, B
    Cassiman, JJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) : 487 - 496
  • [5] Sweat-testing in preterm and full-term infants less than 6 weeks of age
    Eng, W
    LeGrys, VA
    Schechter, MS
    Laughon, MM
    Barker, PM
    [J]. PEDIATRIC PULMONOLOGY, 2005, 40 (01) : 64 - 67
  • [6] Is newborn screening for cystic fibrosis a basic human right?
    Farrell, Philip M.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (03) : 262 - 265
  • [7] Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign
    Groman, JD
    Hefferon, TW
    Casals, T
    Bassas, LS
    Estivill, X
    Des Georges, M
    Guittard, C
    Koudova, M
    Fallin, MD
    Nemeth, K
    Fekete, G
    Kadasi, L
    Friedman, K
    Schwarz, M
    Bombieri, C
    Pignatti, PF
    Kanavakis, E
    Tzetis, M
    Schwartz, M
    Novelli, G
    D'Apice, MR
    Sobczynska-Tomaszewska, A
    Bal, J
    Stuhrmann, M
    Macek, M
    Claustres, M
    Cutting, GR
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 74 (01) : 176 - 179
  • [8] Diagnostic sweat testing: The cystic fibrosis foundation guidelines
    LeGrys, Vicky A.
    Yankaskas, James R.
    Quittell, Lynne M.
    Marshall, Bruce C.
    Mcgayzel, Peter J., Jr.
    [J]. JOURNAL OF PEDIATRICS, 2007, 151 (01) : 85 - 89
  • [9] Pancreatic function and extended mutation analysis in ΔF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels
    Massie, RJ
    Wilcken, B
    Van Asperen, P
    Dorney, S
    Gruca, M
    Wiley, V
    Gaskin, K
    [J]. JOURNAL OF PEDIATRICS, 2000, 137 (02) : 214 - 220
  • [10] Merelle ME., 2001, Cochrane Database Syst Rev, DOI DOI 10.1002/14651858.CD001402